We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery
News

Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery

Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery
News

Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cenix BioScience GmbH, has announced that, together with its new subsidiary, Cenix BioScience Belgium bvba (“Cenix”), it has signed a Collaboration and Technology License Agreement with Beerse, Belgium-based Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”), to improve the in vivo applicability of siRNA-based experimentation, focusing on the further co-development of DARE™, a proprietary Cenix siRNA delivery technology.

The new agreement represents a significant intensification of the research collaboration between Cenix and Janssen ongoing over the past two years, to improve siRNA-based target validation methodologies in vivo for use with CNS indications.

The collaboration will also continue making in-depth use of the full range of Cenix strengths in siRNA-based research, including both its well-established high-throughput, high-content RNAi platform for detailed analyses of subcellular delivery paths and its still-growing in vivo RNAi unit using rodent models for several disease areas.

Some of the novel delivery solutions co-developed by the two partners are also expected to carry strong potential for enabling therapeutic applications of siRNAs, including future improvements to DARE™ technology, which will continue to be owned and controlled by Cenix.

“We are very excited to combine the capabilities of our Dresden and Flanders units with those of our expert colleagues at Janssen,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “We expect that the complementary knowledge and expertise between our teams will further accelerate what has already been a particularly harmonious and productive collaboration.”
Advertisement